2,063 Shares in Cencora, Inc. $COR Bought by Lpwm LLC

Lpwm LLC purchased a new stake in Cencora, Inc. (NYSE:COR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,063 shares of the company’s stock, valued at approximately $697,000.

A number of other institutional investors also recently bought and sold shares of COR. Board of the Pension Protection Fund purchased a new position in shares of Cencora in the 4th quarter valued at about $41,000. Park Avenue Securities LLC lifted its stake in Cencora by 2.3% during the fourth quarter. Park Avenue Securities LLC now owns 16,179 shares of the company’s stock worth $5,465,000 after purchasing an additional 364 shares during the last quarter. Union Bancaire Privee UBP SA boosted its holdings in Cencora by 4.9% in the fourth quarter. Union Bancaire Privee UBP SA now owns 2,381 shares of the company’s stock valued at $810,000 after purchasing an additional 112 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Cencora by 11.9% in the fourth quarter. GAMMA Investing LLC now owns 8,332 shares of the company’s stock valued at $2,814,000 after purchasing an additional 883 shares in the last quarter. Finally, Insight Wealth Strategies LLC increased its stake in Cencora by 1.0% in the fourth quarter. Insight Wealth Strategies LLC now owns 17,472 shares of the company’s stock valued at $5,901,000 after purchasing an additional 176 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Leerink Partners reissued an “outperform” rating on shares of Cencora in a report on Tuesday. Bank of America lowered their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a report on Monday, January 5th. Wells Fargo & Company lifted their price target on shares of Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research report on Tuesday, February 10th. Finally, Evercore restated an “outperform” rating on shares of Cencora in a research note on Tuesday. Twelve research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $403.17.

Insider Buying and Selling

In other news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.38% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR opened at $332.06 on Friday. The stock has a market cap of $64.59 billion, a P/E ratio of 39.91, a P/E/G ratio of 1.51 and a beta of 0.68. Cencora, Inc. has a twelve month low of $264.33 and a twelve month high of $377.54. The stock has a 50 day moving average of $355.08 and a two-hundred day moving average of $339.36. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period last year, the firm posted $3.73 earnings per share. On average, research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.